When coupled with NCCN-oriented prompts such as recommending TP53 or IGHV testing in CLL, or molecular milestone tracking in CML these systems can bridge the gap between computational detection and therapeutic action. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.